Header Graphic
Articles relevant to CM101 and HP59

1. Hellerqvist CG, Rojas J, Green RS, Sell S, Sundell H, Stahlman MT: Studies on group B ß-hemolytic
Streptococcus. I. Isolation and partial characterization of an extracellular toxin. Pediatr Res 15, 892 (1981).

2. Hellerqvist CG, Thurman GB, Page DL, Wang Y-F, Russell BA, Montgomery CA, Sundell HW: Anti-tumor
effects of GBS toxin: A polysaccharide exotoxin from Group B beta-hemolytic streptococcus. Canc Res Clin
Oncol 120, 63-70 (1993).

3. Thurman GB, Russell BA, York GE, Wang Y-F, Page DL, Sundell HW, Hellerqvist CG: Effects of GBS toxin
on long-term survival of mice bearing transplanted Madison lung tumors. J Canc Res Clin Oncol 120, 479-484

4. Sandberg K, Edberg KE, Fish W, Parker R, Hellerqvist CG, Sundell HW: Thromboxane receptor blockage
(SQ 29548) in Group B streptococcal (GBS) toxin challenge in young lambs. Pediatr Res 35, 571-579 (1994).

5. Quinn TE, Thurman GB, Sundell A-K, Zhang M, Hellerqvist CG: CM101, a polysaccharide anti-tumor agent,
does not inhibit wound healing In murine models. J Canc Res Clin Oncol, 121, 253-256 (1995).

6. Thurman GB, Page DL, Wamil BD, Wilkinson LE, Kasami M, Hellerqvist CG: Acute inflammatory changes
in subcutaneous microtumors in mice ears induced by intravenous CM101 (GBS toxin). J Canc Res Clin
Oncol, 122, 549-553 (1996).

7. Wamil BD, Thurman GB, DeVore RF, Wakefield G, Johnson DH, Hellerqvist CG: Soluble E-Selectin in
cancer patients as a marker of the therapeutic efficacy of CM101, a tumor inhibiting agent, evaluated in phase I
clinical trial.

8. DeVore RF, Hellerqvist CG, Wakefield GB, Wamil BD, Thurman GB, Minton PA, Sundell HW, Yan H-P,
Carter CE, Wang Y-F, York GE, Zhang M-H, Johnson DH.: A phase I study of the antineovascularization drug
CM101. J Clin Canc Res, 3, 365-372 (1997).

9. Venkov C, Vorobieff N, Wamil B, Sun F, Yakes M, Hellerqvist C: A quantitative assay using basement
membrane extracts and embryonic stem cells to study the effects of estrogen on developing vascular
endothelium in vivo. Proceedings of the 20th European Conference on Microcirculation. P.H. Carpentier, E.
Vicaut and J.-L. Guilmot, Eds. Monduzzi Editore. Pages 213-217 (1998).

10. Wamil AW, Wamil BD, Hellerqvist CG: CM101-mediated recovery of walking ability in adult mice paralyzed
by spinal cord injury. Proc Natl Acad Sci USA 95, 13188-13193 (1998).

11. Yan H-P, Carter CE, Wang E-Z, Page DL, Washington K, Wamil BW, Yakes FM, Thurman GB, and
Hellerqvist, CG: Functional studies on the anti-pathoangiogenic properties of CM101. Angiogenesis 2, 219-
233 (1998).

12. Yakes FM, Wamil BD, Sun F, Yan H-P, Carter CE and Hellerqvist CG: CM101 treatment overrides tumor-induced
immunoprivilege leading to apoptosis. Cancer Research 60:5740-5746 (2000).

13. Sundell HW, Yan H-P, Wamil BD, Carter CE, Stahlman MT, Hellerqvist CG. Isolation and identification of a
Group B b-hemolytic streptococcal toxin from septic infants. J Pediatrics 137:338-344 (2000).

14. Fu C, Bardhan S, Cetateanu ND, Wamil BD, WangY, Yan H-P, Carter CE, Shi E, Venkov C, Yakes FM,
Page DL, Lloyd RS, Hellerqvist CG. Identification of a novel membrane protein HP59 with therapeutic potential
as a target of tumor angiogenesis. Clin. Cancer Research 7:4182-4194 (2001).

15. Nanney LB, Wamil BD, Whitsitt J,Cardwell NL, Davidson JM, Yan H-P,Hellerqvist CG. CM101 stimulates
cutaneous wound healing through an anti-angiogenic mechanism. Angiogenesis 4: 61-70 (2001).

16. Ohlsson M, Mattson P, Wamil BD, Hellerqvist CG, Svenson M. Macrophage stimulation using a Group B
streptococcus exotoxin (CM101) leads to axonal regrowth in the injured optic nerve. Restorative Neurology and
Neuroscience. 22: 33-41 (2004)